Literature DB >> 9764032

Management of Helicobacter pylori infection in children.

G Oderda1.   

Abstract

When trying to decide which children with Helicobacter pylori infection should be treated and at what stage they should be tested, we should take into account the fact that eradication of the infection may be useful both to induce symptom remission and to prevent later complications in adulthood. However, well designed studies to identify those infected children who are at risk of developing complications or have symptoms due to the infection are still lacking. Current literature only gives information on how to treat children with H pylori infection. Treatment regimens that include two drugs are usually more effective than in adults, and produce an eradication rate of 70-80%, but they should be given for at least two weeks, shorter treatments being less effective. Antibiotic resistance can impair eradication rate and the frequency of resistant strains in children should be studied. Combinations of antibiotics with antisecretory drugs are highly effective in adults, but triple therapy with two antibiotics and an antisecretory drug has been seldom tried in children; compliance is often poor so that the eradication rate is often similar to that produced by dual therapy. Compliance strongly influences eradication, and short simple treatment regimens that produce rapid symptom remission with few side effects are needed to optimise patient compliance. After treatment, eradication must be proved. Serological tests can help, provided that pretreatment serum is available and three to six months have passed since the treatment. A 13C-ureabreath test (13C-UBT) should be performed at least six weeks after treatment, but false negative results can occur and cut-off must be adjusted.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9764032      PMCID: PMC1766603          DOI: 10.1136/gut.43.2008.s10

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  26 in total

1.  Recurrent abdominal pains: a field survey of 1,000 school children.

Authors:  J APLEY; N NAISH
Journal:  Arch Dis Child       Date:  1958-04       Impact factor: 3.791

2.  The transmission of Helicobacter pylori: which theory fits the facts?

Authors:  A T Axon
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-01       Impact factor: 2.566

3.  One week treatment for Helicobacter pylori infection.

Authors:  D Walsh; N Goggin; M Rowland; M Durnin; S Moriarty; B Drumm
Journal:  Arch Dis Child       Date:  1997-04       Impact factor: 3.791

4.  Carbon 13-labeled urea breath test for the diagnosis of Helicobacter pylori infection in children.

Authors:  M Rowland; I Lambert; S Gormally; L E Daly; J E Thomas; C Hetherington; M Durnin; B Drumm
Journal:  J Pediatr       Date:  1997-12       Impact factor: 4.406

5.  Association of symptoms with Helicobacter pylori infection in children.

Authors:  S M Gormally; N Prakash; M T Durnin; L E Daly; M Clyne; B M Kierce; B Drumm
Journal:  J Pediatr       Date:  1995-05       Impact factor: 4.406

6.  Treatment of Campylobacter pylori-associated antral gastritis in children with bismuth subsalicylate and ampicillin.

Authors:  B Drumm; P Sherman; D Chiasson; M Karmali; E Cutz
Journal:  J Pediatr       Date:  1988-11       Impact factor: 4.406

7.  Campylobacter pylori gastritis: long term results of treatment with amoxycillin.

Authors:  G Oderda; D Dell'Olio; I Morra; N Ansaldi
Journal:  Arch Dis Child       Date:  1989-03       Impact factor: 3.791

8.  Management and response to treatment of Helicobacter pylori gastritis.

Authors:  M J Mahony; J I Wyatt; J M Littlewood
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

9.  Helicobacter pylori infection in children: clinical, endoscopic, and histologic correlations.

Authors:  G Prieto; I Polanco; J Larrauri; L Rota; R Lama; S Carrasco
Journal:  J Pediatr Gastroenterol Nutr       Date:  1992-05       Impact factor: 2.839

10.  Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach.

Authors:  M J Blaser; G I Perez-Perez; H Kleanthous; T L Cover; R M Peek; P H Chyou; G N Stemmermann; A Nomura
Journal:  Cancer Res       Date:  1995-05-15       Impact factor: 12.701

View more
  5 in total

1.  Helicobacter pylori infection.

Authors:  Yvan Vandenplas
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

Review 2.  What do we know about benefits of H. pylori treatment in childhood?

Authors:  Mónica S Sierra; Emily V Hastings; Karen J Goodman
Journal:  Gut Microbes       Date:  2013-11-06

3.  Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome.

Authors:  M E Street; P Caruana; C Caffarelli; W Magliani; M Manfredi; F Fornaroli; G L de'Angelis
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

4.  Apoptosis, proliferation and p53 gene expression of H. pylori associated gastric epithelial lesions.

Authors:  Z Zhang; Y Yuan; H Gao; M Dong; L Wang; Y H Gong
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

5.  The updated JSPGHAN guidelines for the management of Helicobacter pylori infection in childhood.

Authors:  Seiichi Kato; Toshiaki Shimizu; Shigeru Toyoda; Benjamin D Gold; Shinobu Ida; Takashi Ishige; Shigeru Fujimura; Shigeru Kamiya; Mutsuko Konno; Kentaro Kuwabara; Kosuke Ushijima; Norikazu Yoshimura; Yoshiko Nakayama
Journal:  Pediatr Int       Date:  2020-12       Impact factor: 1.524

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.